Rubius Therapeutics (NASDAQ: RUBY)
Q3 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED)2022-11-07 | ||||||
REV |
Q2 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -0.530 | -0.490 | 0.0400 | ||||
REV | 0 |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|
You can purchase shares of Rubius Therapeutics (NASDAQ: RUBY) through any online brokerage.
Other companies in Rubius Therapeutics’s space includes: Orchard Therapeutics (NASDAQ:ORTX), Evaxion Biotech (NASDAQ:EVAX), Aligos Therapeutics (NASDAQ:ALGS), Gemini Therapeutics (NASDAQ:GMTX) and Sensei Biotherapeutics (NASDAQ:SNSE).
The latest price target for Rubius Therapeutics (NASDAQ: RUBY) was reported by SVB Leerink on Tuesday, August 9, 2022. The analyst firm set a price target for 1.00 expecting RUBY to rise to within 12 months (a possible 42.25% upside). 10 analyst firms have reported ratings in the last year.
The stock price for Rubius Therapeutics (NASDAQ: RUBY) is $0.703 last updated Today at August 19, 2022, 8:00 PM UTC.
There are no upcoming dividends for Rubius Therapeutics.
Rubius Therapeutics’s Q3 earnings are confirmed for Monday, November 7, 2022.
There is no upcoming split for Rubius Therapeutics.
Rubius Therapeutics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.